UBS reiterates Cencora stock rating on EyeSouth retina deal By Investing.com

$1.1 billion acquisition of EyeSouth Partners’ retina business announced; the acquired retina platform generated >$600M in revenue and ~ $75M in EBITDA in 2022 and is expected to be slightly accretive to adjusted EPS in the first 12 months. UBS (Buy, $410), Evercore ISI (Outperform, $420) and Leerink (Outperform, $447) reiterated positive ratings while BofA stayed Neutral ($380); shares cited at $321 versus a Fair Value indicating upside. Deal to be funded with existing credit facilities and cash, fiscal 2026 guidance was reaffirmed, and CFO James Cleary (7.5 years) announced his retirement.

Analysis

Cencora’s push to vertically integrate specialty ophthalmology practices is a margin story more than a top-line one: by converting buy-and-bill flows into MSO-controlled billing and capture, expect incremental gross margin on drug-administered services to rise materially — think 300–500bps of EBITDA expansion on the acquired footprint within 12–24 months if referral and adherence metrics hold. That uplift is not just AMB (add-on margin) — it creates optionality for higher take-rates on specialty pharmacy distribution, preferred-supplier deals with retina drug manufacturers, and faster enrollment into sponsored trials, which compounds value beyond one-time revenue recognition.

Key near-term risks are execution and payor dynamics. Integration hiccups (scheduling/IT/billing consolidation) can push expected accretion out by 6–12 months and materially depress short-term operating leverage; separately, accelerated biosimilar uptake or tighter prior-authorization protocols in ophthalmology could shave 5–10% off anticipated drug margin capture over a 2–3 year window. Management transition amplifies these execution risks — a successor misstep could delay EBITDA synergies and elevate stock volatility for several quarters.

From a capital structure perspective, using credit lines to fund tuck-ins compresses optionality for tuck-ins that could meaningfully expand recurring revenue (MSO rollout, clinical trial services) and tightens covenant/leverage headroom during any macro-induced revenue softness over the next 12–36 months. The consensus upside appears to underprice the combination of (a) repeatable per-provider margin lift from MSO scale and (b) optionality from improved trial enrollment; however, the market is right to demand concrete 3–6 month integration milestones before re-rating fully.

Key Decisions for Investors

• Buy COR (core position) with a 12-month horizon: target +30% upside, hard stop -12%. Size as 3–5% of equity book. Rationale: capture MSO accretion thesis while allowing time for 12–18 month integration cycle.
• Buy COR 12–18 month call spread (debit): long Jan-2027 call / short Jan-2027 higher strike call to cap cost. Aim for 3:1 upside vs premium; max loss = premium. Use to lever expected EBITDA multiple expansion without funding full equity exposure.
• Pair trade to isolate MSO execution: long COR / short MCK or long COR / short ABC (ratio 1:0.6) for 6–12 months. This hedges broad distribution margin risk and isolates value from clinic-level integration and trial-enrollment optionality.
• Event hedge during CFO succession: buy 3-month protective puts (modest size) or a put spread to limit downside from near-term volatility spikes tied to management appointment and first-quarter integration updates. Expect IV to rise on governance uncertainty; structure to be cost-effective.